NCT04078295 - A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Solid Neoplasms

Interventions

DRUG

E7389-LF

E7389-LF Intravenous infusion.

DRUG

Nivolumab

Nivolumab Intravenous infusion.

Trial Locations (19)

Eisai Trial Site #13, Nagoya

Eisai Trial Site #18, Kashiwa

Eisai Trial Site #2, Kashiwa

Eisai Trial Site #14, Matsuya

Eisai Trial Site #4, Kurume

Eisai Trial Site #11, Akashi

Eisai Trial Site #15, Yokohama

Eisai Trial Site #3, Sendai

Eisai Trial Site #6, Chuo Ku

Eisai Trial Site #8, Chuo Ku

Eisai Trial Site #5, Osakasa

Eisai Trial Site #7, Sakai C

Eisai Trial Site #17, Suita

Eisai Trial Site #19, Kitaadachi-gun

Eisai Trail Site #16, Sunto-g

Eisai Trial Site #1, Chuo Ku

Eisai Trial Site #10, Koto-Ku

Eisai Trial Site #9, Wakayama

Eisai Trial Site #12, Kōtoku